Acerus Pharmaceuticals Corporation represents values of innovation, excellence, and patient-focused healthcare. With a strong commitment to developing and commercializing novel pharmaceutical products, Acerus strives to address unmet medical needs and improve patients' quality of life. The company's corporate philosophy emphasizes scientific expertise, ethical practices, and a dedication to delivering safe and effective therapies. Acerus Pharmaceuticals Corporation places a high value on collaboration with healthcare professionals and leveraging advanced technologies to drive medical advancements. Through its commitment to these values and philosophy, Acerus aims to make a positive impact on the healthcare industry and provide innovative solutions for patients worldwide.

Acerus Pharmaceuticals Corporation is primarily present in Canada and the United States.

Acerus Pharmaceuticals Corporation has achieved several significant milestones. The company successfully gained approval for multiple products, including NATESTO®, a nasal testosterone gel for the treatment of male hypogonadism. Acerus also expanded its product portfolio by launching GYNOFLOR™ in several European countries, as well as acquiring rights to Estrace® from Warner Chilcott. Moreover, Acerus Pharmaceuticals Corporation established partnerships with various pharmaceutical companies to enhance its market reach and facilitate commercialization efforts. These milestones highlight Acerus' commitment to advancing pharmaceutical solutions and expanding its presence in the industry.

Acerus Pharmaceuticals Corporation is a renowned biopharmaceutical company founded in 2008. Headquartered in Toronto, Canada, the company specializes in developing and commercializing innovative therapies. Acerus focuses on men's health, particularly in the field of urology and andrology. With a strong emphasis on research and development, Acerus aims to address unmet medical needs and improve patients' quality of life. Through strategic collaborations and partnerships, the company has expanded its global reach and continues to introduce cutting-edge therapeutic solutions. Acerus Pharmaceuticals Corporation has established itself as a trusted leader in the healthcare industry, consistently pursuing advancements in pharmaceutical sciences.

Some of the main competitors of Acerus Pharmaceuticals Corporation in the market include other pharmaceutical companies such as Pfizer, Johnson & Johnson, and Novartis.

Acerus Pharmaceuticals Corporation primarily operates in the pharmaceutical industry.

The business model of Acerus Pharmaceuticals Corporation is focused on the development, manufacturing, and commercialization of innovative pharmaceutical products. Acerus aims to provide high-quality, scientifically advanced solutions to address various medical conditions. The company specializes in men's health products, particularly in the area of urology. Acerus Pharmaceuticals Corporation utilizes strategic partnerships and licensing agreements to maximize its market reach and accelerate global expansion. By leveraging its expertise and resources, Acerus strives to improve patients' lives and deliver value to its shareholders through the successful commercialization of its pharmaceutical offerings.

De K/W-verhouding kan momenteel niet worden berekend voor Acerus Pharmaceuticals.

De KUV kan momenteel niet worden berekend voor Acerus Pharmaceuticals.

De AlleAktien Kwaliteitsscore voor Acerus Pharmaceuticals is 4/10.

De omzet kan momenteel niet worden berekend voor Acerus Pharmaceuticals.

De winst kan momenteel niet berekend worden voor Acerus Pharmaceuticals.

Acerus Pharmaceuticals Corporation is a pharmaceutical company specializing in the development and marketing of high-quality medications. It was founded in 2008 and is based in Canada. Acerus aims to improve global healthcare by offering innovative products that enhance patients' lives and promote their health. The company operates in three business areas: urology, cardiology, and gynecology. In the urology field, Acerus has developed a wide portfolio of products for the treatment of urogenital system disorders. These products include NATESTO®, a nasal spray for men with low testosterone levels, and EDEX®, an injectable medication for the treatment of erectile dysfunction. In the cardiology field, Acerus has developed an innovative product called GYNOFLOR®, a treatment for vaginal infections in women. This product promises to reduce the risk of relapses and effectively alleviate symptoms. In the gynecology field, Acerus also offers NORMACOL®, a natural preparation for the treatment of constipation during pregnancy and lactation, as well as the hormone preparation CRINONE® for the treatment of female infertility. Acerus' business model is based on collaboration with partners in the medical and pharmaceutical industry to develop and market innovative products. The company conducts intensive research and development to create new treatment options for patients and optimize existing products. Acerus has a strong distribution strategy to ensure successful product launches in target markets. The company has distribution agreements with leading pharmaceutical companies in North America and Europe and strives to expand its presence in global markets. In summary, Acerus Pharmaceuticals Corporation is an innovative pharmaceutical company specializing in the development and marketing of products in the fields of urology, cardiology, and gynecology. The company works closely with partners in the medical and pharmaceutical industry to develop and market innovative products. Acerus has a strong distribution strategy and is committed to expanding its presence in global markets to enable better healthcare for patients worldwide.

Acerus Pharmaceuticals keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Acerus Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van Acerus Pharmaceuticals is CA00444G1081.

Het WKN van Acerus Pharmaceuticals is A14Z7X.

De ticker van Acerus Pharmaceuticals is ASP.TO.

Binnen de laatste 12 maanden betaalde Acerus Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Acerus Pharmaceuticals naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Acerus Pharmaceuticals is momenteel .

Acerus Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Acerus Pharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Acerus Pharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Acerus Pharmaceuticals van 21-9-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 21-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 21-9-2024.

In het jaar 2023 heeft Acerus Pharmaceuticals 0 USD aan dividenden uitgekeerd.

De dividenden van Acerus Pharmaceuticals worden in USD uitgekeerd.